AIkido Pharma Inc. (AIKI): Price and Financial Metrics


AIkido Pharma Inc. (AIKI): $5.84

0.18 (+3.18%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add AIKI to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

AIKI Stock Price Chart Interactive Chart >

Price chart for AIKI

AIKI Price/Volume Stats

Current price $5.84 52-week high $17.51
Prev. close $5.66 52-week low $4.30
Day low $5.64 Volume 62,000
Day high $5.89 Avg. volume 94,478
50-day MA $5.52 Dividend yield N/A
200-day MA $9.36 Market Cap 30.67M

AIkido Pharma Inc. (AIKI) Company Bio


Spherix Incorporated, a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. Its pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. The company's platform consists of patented technology from leading universities and researchers and in the process of developing an innovative therapeutic drug platform through partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. It has a scientific research agreement with The University of Texas Southwestern Medical Center to use machine learning to find genetic markers in people that indicate an increased risk of developing pancreatic cancer. Spherix Incorporated was founded in 1967 and is based in New York, New York.


AIKI Latest News Stream


Event/Time News Detail
Loading, please wait...

AIKI Latest Social Stream


Loading social stream, please wait...

View Full AIKI Social Stream

Latest AIKI News From Around the Web

Below are the latest news stories about AIkido Pharma Inc that investors may wish to consider to help them evaluate AIKI as an investment opportunity.

AIkido Pharma: Advancing Anticancer And Antiviral Therapies

No summary available.

Seeking Alpha | February 10, 2022

AIkido Pharma announces $3M share repurchase program

AIkido Pharma (AIKI +0.8%) has authorized a buyback program to repurchase up to $3M of the company's outstanding common stock, effective immediately. This represents 7% of total market cap of $42.07M. "The Board's decision to establish this share repurchase program reflects the Company's commitment to creating shareholder value, our strong balance...

Seeking Alpha | January 24, 2022

AIkido Pharma Announces Share Repurchase Program

AIkido Pharma Inc. (NASDAQ: AIKI ) ("AIkido" or the "Company"), a clinical and early-stage drug development company, today announced that its board of directors (the "Board") has authorized a share repurchase program to repurchase up to $3 million of the Company's outstanding common stock. The share repurchase authorization is effective immediately.

Yahoo | January 24, 2022

AIkido Pharma Announces Dr. Rachel Yehuda's Appearance on CBS News

AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that Dr. Rachel Yehuda appeared on CBS News discussing the results of a recent FDA-approved trial using a psychedelic drug. CBS News national security correspondent David Martin talks with a former Marine whose two tours in Iraq presaged twelve years of nightmares, panic attacks and failed relationships – and who now finds hope. The video segment is available at:

Yahoo | January 5, 2022

Volatility Of AIkido Pharma Inc. (AIKI) Reaches 5.70%: Make Sure To Keep Your Seat Tight!

AIkido Pharma Inc. (NASDAQ:AIKI) concluded the trading at $0.63 on Wednesday, December 22 with a fall of -2.28% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $0.65 and 5Y monthly beta was reading 1.53 with its price kept floating in the Volatility Of AIkido Pharma Inc. (AIKI) Reaches 5.70%: Make Sure To Keep Your Seat Tight! Read More »

Stocks Register | December 23, 2021

Read More 'AIKI' Stories Here

AIKI Price Returns

1-mo 13.56%
3-mo -25.16%
6-mo -43.46%
1-year -66.15%
3-year -85.69%
5-year -92.78%
YTD -41.48%
2021 -32.80%
2020 -33.83%
2019 -51.47%
2018 -54.29%
2017 34.62%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.545 seconds.